Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma

Multidisciplinary Respiratory Medicine

Original research article

Open Access

• Roberto W. Dal NegroEmail author,
• Luca Bonadiman and
• Paola Turco

Multidisciplinary Respiratory Medicine201813:18

https://doi.org/10.1186/s40248-018-0131-x

Abstract

Background

Bronchial asthma is an inflammatory disease of the airways. Beclomethasone dipropionate/Formoterol (BDP/F) and Fluticasone furoate/Vilanterol (FF/V) are two of the most effective LABA/ICS combinations for managing persistent bronchial asthma.

The impact of cold on the respiratory tract and its consequences to respiratory health

Review

Open Access

Clinical and Translational Allergy

• Maria D’Amato,
• Antonio Molino,
• Giovanna Calabrese,
• Lorenzo Cecchi,
• Isabella Annesi-MaesanoView ORCID ID profile and
• Gennaro D’AmatoEmail author

Clinical and Translational Allergy20188:20

https://doi.org/10.1186/s13601-018-0208-9

Abstract

The increasing use, and sometimes the abuse, particularly in industrialized countries of air conditioning at home, in car, hotel and shopping centres has highlighted new emerging public health issues, resulting from exposure of the airways to cool air or, more properly, resulting from sudden temperature changes.

Case report presenting the diagnostic challenges in a patient with recurrent acquired angioedema, antiphospholipid antibodies and undetectable C2 levels

Allergy, Asthma & Clinical Immunology Case report

Open Access

• Arturo J. BonninEmail author,
• Charles DeBrosse,
• Terri Moncrief and
• G. Wendell Richmond

Allergy, Asthma & Clinical Immunology201814:24

https://doi.org/10.1186/s13223-018-0246-9

Abstract

Background

Angioedema secondary to acquired C1 inhibitor deficiency (AAE) is a rare disease. It usually is associated with lymphoproliferative disorders. We present a case of AAE in a patient with antiphospholipid syndrome (APS), a non-Hodgkin lymphoproliferative disorder (NHL) with undetectable levels of C2, C4, and an undetectable CH50. The co-existence of AAE, APS, and NHL, with an undetectable C2 level, to the best of our knowledge, has never before reported together in the same patient.

Anaesthesia, Surgery and Life-Threatening Allergic Reaction

NAP6 Report

Anaesthesia, Surgery and Life-Threatening Allergic Reactions

Report and findings of the Royal College of Anaesthetists' 6th National Audit Project

NAP6: Perioperative Anaphylaxis is the largest ever prospective study of anaphylaxis related to anaesthesia and surgery.

The full NAP6 Report is available in full as a single PDF, or as individual chapters below.

Some key findings of NAP6 are summarised on the NAP6 Infographic.
 NAP6 Infographic.pdf (718 KB)

Full Report

 NAP6-REPORT-2018 FINAL.pdf (11.75 MB)

Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms

Journal of Immunology Research
Volume 2018, Article ID 5163129, 10 pages
https://doi.org/10.1155/2018/5163129

Review Article

Hideaki Watanabe

Department of Dermatology, Showa University School of Medicine, Tokyo, Japan

Correspondence should be addressed to Hideaki Watanabe; hwatanabe@med.showa-u.ac.jp

Copyright © 2018 Hideaki Watanabe. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Drug-induced hypersensitivity syndrome (DIHS), also termed as drug reaction with eosinophilia and systemic symptoms (DRESS), is a multiorgan systemic reaction characterized by a close relationship with the reactivation of herpes virus. Published data has demonstrated that among patients with DIHS/DRESS, 75–95% have leukocytosis, 18.2–90% show atypical lymphocytes, 52–95% have eosinophilia, and 75–100% have hepatic abnormalities. Histologically, eosinophils were observed less frequently than we expected (20%). The mainstay of DIHS/DRESS treatment is a moderate dose of systemic corticosteroids, followed by gradual dose reduction.

The Microbiome and Risk for Atherosclerosis

Viewpoint

Anthony L. Komaroff, MD¹

Author Affiliations Article Information

JAMA. Published online May 14, 2018. doi:10.1001/jama.2018.5240

Hot new areas of biomedicine sometimes generate cool skepticism. Little more than a decade ago, investigators proposed that the gut microbiome might be contributing to obesity. Since then, the microbiome has been linked to numerous major diseases, including atherosclerosis, although some have been skeptical about this association.

Atopic dermatitis: a review of topical nonsteroid therapy

• Drugs Context
• v.7; 2018
• PMC5886549

Drugs Context. 2018; 7: 212521.

Published online 2018 Apr 3. doi:  10.7573/dic.212521

PMCID: PMC5886549

PMID: 29632548

Ariana Papier, BA1 and Lindsay C Strowd, MD2

Author information ► Article notes ► Copyright and License information ► Disclaimer

Abstract
Background
Atopic dermatitis is a chronic inflammatory skin condition that affects up to 20% of children and 3% of adults globally. Although topical corticosteroids are considered to be the first-line agents, they can be associated with cutaneous and systemic adverse effects. Since the early 2000s, two new classes of nonsteroid topical therapies, topical calcineurin inhibitors and phosphodiesterase 4 (PDE4) inhibitors, have been introduced and provide a safe treatment alternative.

An update on molecular cat allergens: Fel d 1 and what else? Chapter 1: Fel d 1, the major cat allergen

B. Bonnet, K. Messaoudi, F. Jacomet, E. Michaud, J. L. Fauquert, D. Caillaud and B. Evrard

Allergy, Asthma & Clinical Immunology 2018, 14:14 | Published on: 10 April 2018 Abstract Background Cats are the major source of indoor inhalant allergens after house dust mites. The global incidence of cat allergies is rising sharply, posing a major public health problem. Ten cat allergens have been identified. The major allergen responsible for symptoms is Fel d 1, a secretoglobin and not a lipocalin, making the cat a special case among mammals.